Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Rating of “Buy” by Analysts

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have earned a consensus rating of “Buy” from the thirteen brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, ten have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $11.6364.

Several research firms recently commented on TSHA. Canaccord Genuity Group boosted their price objective on shares of Taysha Gene Therapies from $14.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, April 6th. Needham & Company LLC boosted their price objective on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, March 19th. Wall Street Zen lowered shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research note on Saturday. Chardan Capital reiterated a “buy” rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, March 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Friday, March 27th.

Insider Transactions at Taysha Gene Therapies

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of the company’s stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $4.46, for a total transaction of $892,000.00. Following the transaction, the insider owned 1,136,410 shares in the company, valued at approximately $5,068,388.60. This represents a 14.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.78% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of TSHA. Vestal Point Capital LP increased its stake in Taysha Gene Therapies by 150.0% during the 4th quarter. Vestal Point Capital LP now owns 13,750,000 shares of the company’s stock valued at $75,625,000 after purchasing an additional 8,250,000 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in Taysha Gene Therapies during the 2nd quarter valued at approximately $11,178,000. Barclays PLC increased its stake in Taysha Gene Therapies by 1,042.8% during the 3rd quarter. Barclays PLC now owns 5,148,112 shares of the company’s stock valued at $16,834,000 after purchasing an additional 4,697,611 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Taysha Gene Therapies during the 4th quarter valued at approximately $20,471,000. Finally, State Street Corp increased its stake in Taysha Gene Therapies by 49.1% during the 4th quarter. State Street Corp now owns 10,790,084 shares of the company’s stock valued at $59,345,000 after purchasing an additional 3,553,619 shares in the last quarter. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Trading Up 2.1%

NASDAQ TSHA opened at $6.81 on Friday. The company has a quick ratio of 12.23, a current ratio of 12.23 and a debt-to-equity ratio of 0.20. The firm has a market cap of $1.96 billion, a PE ratio of -17.92 and a beta of 1.25. The company has a 50 day moving average price of $5.07 and a 200 day moving average price of $4.93. Taysha Gene Therapies has a 52 week low of $2.06 and a 52 week high of $7.30.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02). As a group, sell-side analysts forecast that Taysha Gene Therapies will post -0.44 EPS for the current fiscal year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.